Myriad signs agreement with Abbott for BRACAnalysis

[News]

Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.

More... (http://www.news-medical.net/news/20101027/Myriad-signs-agreement-with-Abbott-for-BRACAnalysis.aspx)